Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin
…, WD Figg, G Niederfellner, V Méresse Naegelen… - Cancer, 2020 - Wiley Online Library
Background LMB‐100 is an antibody‐toxin conjugate with an antimesothelin Fab linked to a
24‐kilodalton portion of Pseudomonas exotoxin A with mutations that decrease …
24‐kilodalton portion of Pseudomonas exotoxin A with mutations that decrease …
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in …
…, JJL Tessier, E Shochat, S Blotner, VM Naegelen… - Clinical Cancer …, 2012 - AACR
Purpose: This phase I study assessed the maximum tolerated dose (MTD), dose-limiting
toxicities (DLT), safety, pharmacokinetics, pharmacodynamics, and clinical activity of the first-in-…
toxicities (DLT), safety, pharmacokinetics, pharmacodynamics, and clinical activity of the first-in-…
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid …
…, JJL Tessier, E Shochat, S Blotner, VM Naegelen… - Clinical Cancer …, 2012 - AACR
Purpose: This phase I study of the mitogen-activated protein/extracellular signal–regulated
kinase inhibitor RO4987655 (CH4987655) assessed its maximum tolerated dose (MTD), dose…
kinase inhibitor RO4987655 (CH4987655) assessed its maximum tolerated dose (MTD), dose…
Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials
…, T Carlier, VM Naegelen… - Journal of Nuclear …, 2012 - Soc Nuclear Med
Two mitogen-activated protein kinase kinase (MAPK2, also known as MEK) inhibitors were
assessed with 18 F-FDG PET in separate phase I clinical studies, clearly illustrating the …
assessed with 18 F-FDG PET in separate phase I clinical studies, clearly illustrating the …
[HTML][HTML] Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
…, TK Nayak, DJ Vugts, R Christen, VM Naegelen… - EJNMMI research, 2018 - Springer
Background Ideally, monoclonal antibodies provide selective treatment by targeting the tumour,
without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in …
without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in …
[HTML][HTML] First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors
Transmembrane glycoprotein CD44 is overexpressed in various malignancies. Interactions
between CD44 and hyaluronic acid are associated with poor prognosis, making CD44 an …
between CD44 and hyaluronic acid are associated with poor prognosis, making CD44 an …
Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF …
…, WEE Eberhardt, M Paques, E Guarin, V Meresse… - Clinical Cancer …, 2014 - AACR
Purpose: This phase I expansion study assessed safety, pharmacodynamic effects, and
antitumor activity of RO4987655, a pure MEK inhibitor, in selected patients with advanced solid …
antitumor activity of RO4987655, a pure MEK inhibitor, in selected patients with advanced solid …
[HTML][HTML] Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches
…, Y Yoshimura, CH Ooi, L Lu, N Mitsios, V Meresse… - Ejnmmi Research, 2014 - Springer
Background Inhibition of mitogen-activated protein kinase (MEK, also known as MAPK2,
MAPKK), a key molecule of the Ras/MAPK (mitogen-activated protein kinase) pathway, has …
MAPKK), a key molecule of the Ras/MAPK (mitogen-activated protein kinase) pathway, has …
[HTML][HTML] [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in …
T Tegnebratt, L Lu, L Lee, V Meresse, J Tessier, N Ishii… - EJNMMI research, 2013 - Springer
Background Positron emission tomography (PET) with [2- 18 F]-2-fluoro-2-deoxy-D-glucose
([ 18 F]FDG-PET) was acquired at multiple time-points a) to monitor the early response to …
([ 18 F]FDG-PET) was acquired at multiple time-points a) to monitor the early response to …
[PDF][PDF] pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models
T Tegnebratt, L Lu, L Lee, V Meresse, J Tessier… - 2013 - ejnmmires.springeropen.com
Methods:[18 F] FDG uptake was studied in HCT116 (K-ras), COLO205 (B-raf) mutants and
COLO320DM (wild type) xenografts from day 0 to 3 of RO5126766 treatment using a …
COLO320DM (wild type) xenografts from day 0 to 3 of RO5126766 treatment using a …